AU2014243773B2 - Neuroactive steroids and methods of use thereof - Google Patents
Neuroactive steroids and methods of use thereof Download PDFInfo
- Publication number
- AU2014243773B2 AU2014243773B2 AU2014243773A AU2014243773A AU2014243773B2 AU 2014243773 B2 AU2014243773 B2 AU 2014243773B2 AU 2014243773 A AU2014243773 A AU 2014243773A AU 2014243773 A AU2014243773 A AU 2014243773A AU 2014243773 B2 AU2014243773 B2 AU 2014243773B2
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- unsubstituted
- compound
- certain embodiments
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1(C)C=NCCC*1 Chemical compound CC1(C)C=NCCC*1 0.000 description 3
- KFNMXUHNHJZIRK-RKDJMYEQSA-N CC(C)C(C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)O Chemical compound CC(C)C(C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)O KFNMXUHNHJZIRK-RKDJMYEQSA-N 0.000 description 2
- HEOYUTKBAGAXSP-LMDOIDTISA-N C[C@H](CC[C@](C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O Chemical compound C[C@H](CC[C@](C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O HEOYUTKBAGAXSP-LMDOIDTISA-N 0.000 description 2
- VXLPTCJCHWUKKV-NFSSVYEPSA-N CCCCC1=CC[C@@H]([C@H](CC2)[C@](C)(CC3)[C@H]2[C@H](C)CCCC(F)(F)F)[C@H]3[C@@]1(C)CC Chemical compound CCCCC1=CC[C@@H]([C@H](CC2)[C@](C)(CC3)[C@H]2[C@H](C)CCCC(F)(F)F)[C@H]3[C@@]1(C)CC VXLPTCJCHWUKKV-NFSSVYEPSA-N 0.000 description 1
- NLHFJIAZBHNOSY-AMIYGGGRSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@@H](C(F)(F)F)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@@H](C(F)(F)F)O)O NLHFJIAZBHNOSY-AMIYGGGRSA-N 0.000 description 1
- ZKVOXHUCRWANHT-SLDOBEGXSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@@H](C)C(F)(F)F)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@@H](C)C(F)(F)F)O ZKVOXHUCRWANHT-SLDOBEGXSA-N 0.000 description 1
- WRWPNZJNPRSDSN-UNDMJTHNSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CC[C@H](C(F)(F)F)O)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CC[C@H](C(F)(F)F)O)[C@H]4[C@@]2(C)CC1)O WRWPNZJNPRSDSN-UNDMJTHNSA-N 0.000 description 1
- UDCASXDDUOLRMT-XOLAWMNISA-N C[C@H](CCC(C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCC(C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 UDCASXDDUOLRMT-XOLAWMNISA-N 0.000 description 1
- HWAIKCHQQOQKDK-GHCDENFXSA-N C[C@H](CCC(C)(CCOC)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCC(C)(CCOC)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 HWAIKCHQQOQKDK-GHCDENFXSA-N 0.000 description 1
- BVBRUQYHUXKZMQ-CNBKNGECSA-N C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)C1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)C1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 BVBRUQYHUXKZMQ-CNBKNGECSA-N 0.000 description 1
- WRTPCXHWTPMXCQ-LMBAJECESA-N C[C@H](CC[C@@](C)(CCCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC[C@@](C)(CCCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 WRTPCXHWTPMXCQ-LMBAJECESA-N 0.000 description 1
- UDCASXDDUOLRMT-MBOCNQOASA-N C[C@H](CC[C@@](C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC[C@@](C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 UDCASXDDUOLRMT-MBOCNQOASA-N 0.000 description 1
- XUIXYHLPAUINEV-CVARHHIYSA-N C[C@H](CC[C@](C)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@@]2(C)O Chemical compound C[C@H](CC[C@](C)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@@]2(C)O XUIXYHLPAUINEV-CVARHHIYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019201275A AU2019201275B2 (en) | 2013-03-13 | 2019-02-22 | Neuroactive steroids and methods of use thereof |
| AU2021200205A AU2021200205B2 (en) | 2013-03-13 | 2021-01-14 | Neuroactive steroids and methods of use thereof |
| AU2022279366A AU2022279366B2 (en) | 2013-03-13 | 2022-11-28 | Neuroactive steroids and methods of use thereof |
| AU2025203021A AU2025203021A1 (en) | 2013-03-13 | 2025-04-29 | Neuroactive steroids and methods of use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779735P | 2013-03-13 | 2013-03-13 | |
| US61/779,735 | 2013-03-13 | ||
| PCT/US2014/026784 WO2014160480A1 (en) | 2013-03-13 | 2014-03-13 | Neuroactive steroids and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201275A Division AU2019201275B2 (en) | 2013-03-13 | 2019-02-22 | Neuroactive steroids and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014243773A1 AU2014243773A1 (en) | 2015-10-01 |
| AU2014243773B2 true AU2014243773B2 (en) | 2018-12-13 |
Family
ID=51625437
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014243773A Active AU2014243773B2 (en) | 2013-03-13 | 2014-03-13 | Neuroactive steroids and methods of use thereof |
| AU2019201275A Active AU2019201275B2 (en) | 2013-03-13 | 2019-02-22 | Neuroactive steroids and methods of use thereof |
| AU2021200205A Active AU2021200205B2 (en) | 2013-03-13 | 2021-01-14 | Neuroactive steroids and methods of use thereof |
| AU2022279366A Active AU2022279366B2 (en) | 2013-03-13 | 2022-11-28 | Neuroactive steroids and methods of use thereof |
| AU2025203021A Pending AU2025203021A1 (en) | 2013-03-13 | 2025-04-29 | Neuroactive steroids and methods of use thereof |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201275A Active AU2019201275B2 (en) | 2013-03-13 | 2019-02-22 | Neuroactive steroids and methods of use thereof |
| AU2021200205A Active AU2021200205B2 (en) | 2013-03-13 | 2021-01-14 | Neuroactive steroids and methods of use thereof |
| AU2022279366A Active AU2022279366B2 (en) | 2013-03-13 | 2022-11-28 | Neuroactive steroids and methods of use thereof |
| AU2025203021A Pending AU2025203021A1 (en) | 2013-03-13 | 2025-04-29 | Neuroactive steroids and methods of use thereof |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US20160031930A1 (enExample) |
| EP (4) | EP2968369B1 (enExample) |
| JP (6) | JP6255082B2 (enExample) |
| CN (3) | CN118702755A (enExample) |
| AU (5) | AU2014243773B2 (enExample) |
| BR (1) | BR112015022174B1 (enExample) |
| CA (2) | CA3114062A1 (enExample) |
| CY (2) | CY1120934T1 (enExample) |
| DK (3) | DK3932932T3 (enExample) |
| ES (3) | ES2699445T3 (enExample) |
| FI (1) | FI3932932T3 (enExample) |
| HR (3) | HRP20181994T1 (enExample) |
| HU (2) | HUE055668T2 (enExample) |
| IL (3) | IL280068B2 (enExample) |
| LT (3) | LT3932932T (enExample) |
| MX (2) | MX388210B (enExample) |
| PL (3) | PL3932932T3 (enExample) |
| PT (3) | PT2968369T (enExample) |
| RS (3) | RS67266B1 (enExample) |
| RU (1) | RU2684103C2 (enExample) |
| SI (3) | SI3932932T1 (enExample) |
| SM (3) | SMT202500336T1 (enExample) |
| TR (1) | TR201817995T4 (enExample) |
| WO (1) | WO2014160480A1 (enExample) |
| ZA (1) | ZA201506729B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1959966B1 (en) | 2005-11-28 | 2020-06-03 | Marinus Pharmaceuticals, Inc. | Ganaxolone formulations and methods for the making and use thereof |
| US9515617B2 (en) | 2010-10-27 | 2016-12-06 | Merus Audio Aps | Audio amplifier using multi-level pulse width modulation |
| WO2013036835A1 (en) | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| RS67266B1 (sr) | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016007762A1 (en) | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
| US20170304321A1 (en) | 2014-10-07 | 2017-10-26 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| SMT202100476T1 (it) * | 2015-07-06 | 2021-09-14 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| JP6882996B2 (ja) * | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| BR112018000129B1 (pt) * | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| SI3436022T1 (sl) * | 2016-04-01 | 2022-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) * | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| US20180042903A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| MX392270B (es) | 2016-09-30 | 2025-03-24 | Sage Therapeutics Inc | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. |
| CN110267966B (zh) * | 2016-10-18 | 2022-07-08 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| EP4105223B1 (en) * | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN106632565A (zh) * | 2016-11-07 | 2017-05-10 | 湖南科瑞生物制药股份有限公司 | 一种合成胆固醇的新方法 |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| WO2020260558A1 (en) | 2019-06-27 | 2020-12-30 | Phenex Pharmaceuticals Ag | 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| IL293525A (en) | 2019-12-06 | 2022-08-01 | Marinus Pharmaceuticals Inc | Ganaxolone for use in the treatment of multiple sclerosis complex |
| US20240252514A1 (en) * | 2021-05-04 | 2024-08-01 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's disease |
| KR20240035444A (ko) | 2021-06-11 | 2024-03-15 | 세이지 테라퓨틱스, 인크. | 알츠하이머병 치료를 위한 신경활성 스테로이드 |
| JP2024532273A (ja) * | 2021-08-25 | 2024-09-05 | セージ セラピューティクス， インコーポレイテッド | ポジティブｎｍｄａモジュレート化合物及びその使用方法 |
| US20240417423A1 (en) * | 2021-09-22 | 2024-12-19 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
| WO2023083979A1 (en) * | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CA3242623A1 (en) * | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of huntington's disease |
| CN114478672B (zh) * | 2022-01-27 | 2024-06-14 | 浙江仙居君业药业有限公司 | 一种he3286的合成方法 |
| IL317904A (en) | 2022-06-24 | 2025-02-01 | Sage Therapeutics Inc | Crystalline forms of neuroactive steroid |
| CA3261849A1 (en) | 2022-07-12 | 2024-01-18 | Sage Therapeutics Inc | CRYSTALLINE FORM OF A NEUROACTIVE STEROID |
| WO2024229290A1 (en) | 2023-05-02 | 2024-11-07 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of use thereof |
| WO2025227053A1 (en) * | 2024-04-25 | 2025-10-30 | Sage Therapeutics, Inc. | Nmda receptor positive allosteric modulatory compositions and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013036835A1 (en) * | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| ATE45347T1 (de) | 1985-05-30 | 1989-08-15 | Taisho Pharmaceutical Co Ltd | Vitamin d3-derivate. |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DK1038880T3 (da) * | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| GEP20002033B (en) | 1994-11-23 | 2000-04-10 | Cocensys Inc Us | Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| CA2223996A1 (en) * | 1995-06-06 | 1996-12-19 | Cocensys, Inc. | Neuroactive steroids of the androstane and pregnane series |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| JPH11507929A (ja) | 1995-06-23 | 1999-07-13 | ノボ ノルディスク アクティーゼルスカブ | 減数分裂調節化合物 |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| EP0840612A1 (en) | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| JP2002514621A (ja) | 1998-05-11 | 2002-05-21 | ノボ ノルディスク アクティーゼルスカブ | 置換グアニジン及びジアミノニトロエテン、それらの製造及び使用 |
| IL139241A0 (en) | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
| CA2331962A1 (en) | 1998-05-13 | 1999-11-18 | Novo Nordisk A/S | Meiosis regulating compounds |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) * | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| WO2002090375A2 (en) * | 2001-05-03 | 2002-11-14 | The University Of Chicago | Liver x receptor agonists |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| WO2003039480A2 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| US20030162758A1 (en) | 2001-12-07 | 2003-08-28 | Schwartz Daniel M. | Treatment for age-related macular degeneration (AMD) |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| WO2003082893A2 (en) | 2002-03-27 | 2003-10-09 | Phytopharm Plc | Theraputic methods and uses of sapogenins and their derivatives |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| US20050142192A1 (en) | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) * | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| DE602005025391D1 (de) | 2004-11-01 | 2011-01-27 | Seo Hong Yoo | Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose |
| WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) * | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| WO2008057468A1 (en) | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| ES2662500T3 (es) | 2006-11-21 | 2018-04-06 | Asarina Pharma Ab | El uso de esteroides de pregnano y androstano para la preparación de una composición farmacéutica para el tratamiento de trastornos del sistema nervioso central |
| AU2008331808B2 (en) | 2007-03-16 | 2014-08-21 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| KR101767849B1 (ko) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논 |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009059239A2 (en) | 2007-11-02 | 2009-05-07 | Mayo Foundation For Medical Education And Research | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
| US20110118353A1 (en) | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| US8273737B2 (en) | 2008-01-25 | 2012-09-25 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| TWI478709B (zh) | 2008-02-19 | 2015-04-01 | Earnest Medicine Co Ltd | A useful oral or enteral composition for the recovery of bodily functions |
| CA2722776A1 (en) | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| CN101683348B (zh) * | 2008-09-23 | 2012-07-04 | 中山大学 | 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010088414A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| CN102939011A (zh) * | 2010-03-03 | 2013-02-20 | 萨托里医药公司 | 用于治疗神经变性病症的化合物 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| WO2012166617A2 (en) | 2011-05-27 | 2012-12-06 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| JP6117191B2 (ja) | 2011-10-07 | 2017-04-19 | 武田薬品工業株式会社 | 神経変性疾患の治療に有用な１−アリールカルボニル−４−オキシ−ピペリジン化合物 |
| CN113234114A (zh) | 2011-10-14 | 2021-08-10 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| EP2841067A4 (en) | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| SG10201706063UA (en) | 2012-12-18 | 2017-09-28 | Univ Washington | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
| JP2016505038A (ja) | 2013-01-23 | 2016-02-18 | スファエラ ファーマ プライベート リミテッド | ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための１１β−ヒドロキシステロイドの新規の化合物 |
| AU2014212487C1 (en) | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| RU2021111681A (ru) | 2013-03-13 | 2021-05-11 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их применение |
| RS67266B1 (sr) * | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| WO2014169832A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| EP3900738A1 (en) | 2014-02-08 | 2021-10-27 | F. Hoffmann-La Roche AG | Methods of treating alzheimer's disease |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016007762A1 (en) | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
| US20170304321A1 (en) | 2014-10-07 | 2017-10-26 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| BR112018000129B1 (pt) | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| SMT202100476T1 (it) | 2015-07-06 | 2021-09-14 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| SI3436022T1 (sl) | 2016-04-01 | 2022-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| MX392270B (es) | 2016-09-30 | 2025-03-24 | Sage Therapeutics Inc | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. |
| CN110267966B (zh) | 2016-10-18 | 2022-07-08 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| BR112019027458A2 (pt) | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | métodos e intermediários para a preparação de derivados de ácidos biliares |
| WO2019094724A1 (en) | 2017-11-10 | 2019-05-16 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
-
2014
- 2014-03-13 RS RS20250988A patent/RS67266B1/sr unknown
- 2014-03-13 ES ES14774060T patent/ES2699445T3/es active Active
- 2014-03-13 CN CN202410694955.5A patent/CN118702755A/zh active Pending
- 2014-03-13 CA CA3114062A patent/CA3114062A1/en not_active Abandoned
- 2014-03-13 PT PT14774060T patent/PT2968369T/pt unknown
- 2014-03-13 SM SM20250336T patent/SMT202500336T1/it unknown
- 2014-03-13 CA CA2905359A patent/CA2905359C/en active Active
- 2014-03-13 EP EP14774060.9A patent/EP2968369B1/en active Active
- 2014-03-13 ES ES21172859T patent/ES3042115T3/es active Active
- 2014-03-13 US US14/775,678 patent/US20160031930A1/en not_active Abandoned
- 2014-03-13 MX MX2019000995A patent/MX388210B/es unknown
- 2014-03-13 LT LTEP21172859.7T patent/LT3932932T/lt unknown
- 2014-03-13 MX MX2015012430A patent/MX362544B/es active IP Right Grant
- 2014-03-13 PT PT181900341T patent/PT3461834T/pt unknown
- 2014-03-13 LT LTEP14774060.9T patent/LT2968369T/lt unknown
- 2014-03-13 ES ES18190034T patent/ES2886506T3/es active Active
- 2014-03-13 IL IL280068A patent/IL280068B2/en unknown
- 2014-03-13 DK DK21172859.7T patent/DK3932932T3/da active
- 2014-03-13 RS RS20181442A patent/RS58166B1/sr unknown
- 2014-03-13 SI SI201432115T patent/SI3932932T1/sl unknown
- 2014-03-13 CN CN201480026165.4A patent/CN105246486B/zh active Active
- 2014-03-13 EP EP25189422.6A patent/EP4643945A2/en active Pending
- 2014-03-13 AU AU2014243773A patent/AU2014243773B2/en active Active
- 2014-03-13 HR HRP20181994TT patent/HRP20181994T1/hr unknown
- 2014-03-13 LT LTEP18190034.1T patent/LT3461834T/lt unknown
- 2014-03-13 BR BR112015022174-2A patent/BR112015022174B1/pt active IP Right Grant
- 2014-03-13 PL PL21172859.7T patent/PL3932932T3/pl unknown
- 2014-03-13 TR TR2018/17995T patent/TR201817995T4/en unknown
- 2014-03-13 SI SI201430981T patent/SI2968369T1/sl unknown
- 2014-03-13 CN CN202011101409.4A patent/CN112375115A/zh active Pending
- 2014-03-13 EP EP18190034.1A patent/EP3461834B1/en active Active
- 2014-03-13 IL IL318314A patent/IL318314A/en unknown
- 2014-03-13 PL PL18190034T patent/PL3461834T3/pl unknown
- 2014-03-13 RU RU2015143466A patent/RU2684103C2/ru active
- 2014-03-13 WO PCT/US2014/026784 patent/WO2014160480A1/en not_active Ceased
- 2014-03-13 HU HUE18190034A patent/HUE055668T2/hu unknown
- 2014-03-13 SI SI201431866T patent/SI3461834T1/sl unknown
- 2014-03-13 SM SM20210475T patent/SMT202100475T1/it unknown
- 2014-03-13 EP EP21172859.7A patent/EP3932932B8/en active Active
- 2014-03-13 DK DK14774060.9T patent/DK2968369T3/en active
- 2014-03-13 RS RS20211011A patent/RS62235B1/sr unknown
- 2014-03-13 PL PL14774060T patent/PL2968369T3/pl unknown
- 2014-03-13 HU HUE21172859A patent/HUE072324T2/hu unknown
- 2014-03-13 DK DK18190034.1T patent/DK3461834T3/da active
- 2014-03-13 PT PT211728597T patent/PT3932932T/pt unknown
- 2014-03-13 FI FIEP21172859.7T patent/FI3932932T3/fi active
- 2014-03-13 SM SM20180657T patent/SMT201800657T1/it unknown
- 2014-03-13 JP JP2016502244A patent/JP6255082B2/ja active Active
- 2014-03-13 HR HRP20251221TT patent/HRP20251221T1/hr unknown
-
2015
- 2015-09-08 IL IL241301A patent/IL241301B/en active IP Right Grant
- 2015-09-10 ZA ZA2015/06729A patent/ZA201506729B/en unknown
-
2017
- 2017-05-05 US US15/588,305 patent/US20170305960A1/en not_active Abandoned
- 2017-12-01 JP JP2017231660A patent/JP6530804B2/ja active Active
-
2018
- 2018-03-09 US US15/917,263 patent/US10227375B2/en active Active
- 2018-11-27 CY CY181101258T patent/CY1120934T1/el unknown
- 2018-12-20 US US16/227,013 patent/US11104701B2/en active Active
-
2019
- 2019-02-22 AU AU2019201275A patent/AU2019201275B2/en active Active
- 2019-05-17 JP JP2019093816A patent/JP2019135261A/ja not_active Withdrawn
-
2021
- 2021-01-14 AU AU2021200205A patent/AU2021200205B2/en active Active
- 2021-07-05 JP JP2021111379A patent/JP7317898B2/ja active Active
- 2021-07-21 US US17/381,829 patent/US11905309B2/en active Active
- 2021-08-10 CY CY20211100713T patent/CY1124629T1/el unknown
- 2021-08-12 HR HRP20211300TT patent/HRP20211300T1/hr unknown
-
2022
- 2022-10-03 JP JP2022159468A patent/JP7715692B2/ja active Active
- 2022-11-28 AU AU2022279366A patent/AU2022279366B2/en active Active
-
2024
- 2024-01-05 US US18/405,657 patent/US20240287125A1/en active Pending
-
2025
- 2025-04-29 AU AU2025203021A patent/AU2025203021A1/en active Pending
- 2025-06-05 JP JP2025094024A patent/JP2025120299A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013036835A1 (en) * | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
Non-Patent Citations (4)
| Title |
|---|
| CONNICK J H ET AL, "Org (1) potentiates NMDA-receptor mediated responses in vivo", 2009 NEUROSCIENCE MEETING PLANNER. CHICAGO, IL; OCTOBER 17 - 21, 2009, SOCIETY FOR NEUROSCIENCE, (2009-10-17), no. Program#/Poster#: 613 1/B86, pages 1 - 2 * |
| S. M. PAUL ET AL, "The Major Brain Cholesterol Metabolite 24(S)-Hydroxycholesterol Is a Potent Allosteric Modulator of N-Methyl-D-Aspartate Receptors", JOURNAL OF NEUROSCIENCE, US, (2013-10-30), vol. 33, no. 44, pages 17290 - 17300 * |
| XILOURI ET AL, "Neuroprotective effects of steroid analogues on P19-N neurons", NEUROCHEMISTRY INTERNATIONAL, PERGAMON PRESS, OXFORD, GB, (2007-03-02), vol. 50, no. 4, doi:10.1016/J.NEUINT.2006.12.010, ISSN 0197-0186, pages 660 - 670 * |
| YOON-SEOK ROH ET AL, "Neuroprotective Effects of Ginsenoside Rg 3 against 24-OH-cholesterol-induced Cytotoxicity in Cortical Neurons", JOURNAL OF GINSENG RESEARCH, KR, (2010-09-30), vol. 34, no. 3, pages 246 - 253 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014243773B2 (en) | Neuroactive steroids and methods of use thereof | |
| HK40066987A (en) | Neuroactive steriods and methods of use thereof | |
| HK40007016A (en) | Neuroactive steroids | |
| HK40007016B (en) | Neuroactive steroids | |
| RU2808166C2 (ru) | Нейроактивные стероиды и способы их применения | |
| HK1220375B (en) | Neuroactive steroids and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |